LENZ Therapeutics, Inc.: BML Investment Partners, L.P. discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 4 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
BML Investment Partners, L.P. disclosed a stake exceeding 5% in LENZ Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001373604-26-000076). The passive-investor disclosure signals meaningful institutional ownership in the eye-care drug developer. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G/13D amendments and any changes in BML's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
BML Investment Partners, L.P., LENZ Therapeutics, Inc.